Open AccessAbstract CT262: Multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in HR-positive, HER2-positive metastatic breast cancer
Author(s) -
Krystal Pauline Cascetta,
Poulikos I. Poulikakos,
Charles L. Shapiro,
Julie Fasano,
Aarti Sonia Bhardwaj,
Hanna Y. Irie,
Anupama Goel,
Paula Klein,
Meng Ru,
Amy Tiersten
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct262
Subject(s) - palbociclib , pertuzumab , trastuzumab , medicine , metastatic breast cancer , anastrozole , oncology , breast cancer , letrozole , lapatinib , trastuzumab emtansine , cancer , aromatase